by: Parent Project Muscular Dystrophy
Catabasis Pharmaceuticals has shared the latest edition of their community newsletter which includes information from their presentations at the Congress of the World Muscle Society. The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension trial are both ongoing and top-line results from the Phase 3 trial are expected later this year. Following the release of results, PPMD will convene a webinar with Catabasis to discuss the results with the community.
